SCHEMBL99082

SCHEMBL99082

CC(C)(Cc1ccc(N)cc1)[N+](=O)[O-]

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.44
ALDH1A1 P00352 3/20 0.43
CYP3A4 P08684 3/20 0.39
TSHR P16473 3/20 0.39
GFER P55789 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
LOXL2 Q9Y4K0 2/20 0.38
LMNA P02545 1/20 0.37
MPO P05164 1/20 0.37
CYP2C9 P11712 1/20 0.37
HTR6 P50406 1/20 0.37
AR P10275 1/20 0.36
CA9 Q16790 4/20 0.36
MEN1 O00255 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36
RECQL P46063 1/20 0.36
EPHX2 P34913 1/20 0.36
ESR1 P03372 1/20 0.36
CYP19A1 P11511 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5527114 0.84 ACHE (0.43) ALDH1A1CYP3A4TSHRTDP1LMNA
SCHEMBL5830105 0.82 ESR1 (0.55) ALDH1A1TSHRMEN1KMT2AESR1
SCHEMBL97944 0.82 LOXL2 (0.52) ALDH1A1TSHRLOXL2CYP2C9
SCHEMBL10305277 0.82 MAPT (0.37) ALDH1A1LMNAMAPTCYP19A1GAA
SCHEMBL4371898 0.82 SLC6A2 (0.48) FDPSALDH1A1CYP3A4LMNACYP2C9
SCHEMBL12802351 0.79 ALDH1A1 (0.55) ALDH1A1MEN1MAPTKMT2A
SCHEMBL28311358 0.78 ESR1 (0.50) ALDH1A1TSHRMEN1KMT2AESR1
SCHEMBL13884484 0.75 ALDH3A1 (0.37) ALDH1A1LMNACA9MAPTEPHX2
SCHEMBL11758080 0.75 HSD11B1 (0.46) ALDH1A1TSHRTDP1LOXL2LMNA
Phenol SCHEMBL28311359 0.74 FNTA (0.42) FDPSALDH1A1CYP3A4TDP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9072734-B2 Quaternary ammonium salt compounds TEIJIN PHARMA LIMITED (JP) 2015-07-07 US disclosed
US-8299123-B2 CCR10 antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-30 US disclosed
US-8299123-B2 CCR10 antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-30 US disclosed
EP-2215065-B1 CCR10 ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2012-07-11 EP disclosed
EP-2426121-A1 QUATERNARY AMMONIUM SALT COMPOUND Teijin Pharma Limited (JP) 2012-03-07 EP disclosed
US-20120046467-A1 QUATERNARY AMMONIUM SALT COMPOUNDS TEIJIN PHARMA LIMITED (JP) 2012-02-23 US disclosed
US-20110039851-A1 CCR10 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-02-17 US disclosed
US-20110039851-A1 CCR10 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-02-17 US disclosed
WO-2009052078-A1 CCR10 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046467-A1 QUATERNARY AMMONIUM SALT COMPOUNDS ADRB2, AGTR2, ADRB3 FDPS 4500/4885ALDH1A1 1896/4885CYP3A4 1694/4885
US-20110039851-A1 CCR10 ANTAGONISTS CCR10, CCR1, CCR4 FDPS 4290/4885ALDH1A1 3036/4885CYP3A4 3900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.